• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's After-Market Session

    3/5/24 4:31:07 PM ET
    $ALDX
    $CARA
    $CERS
    $CMAX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALDX alert in real time by email

    Gainers

    • NKGen Biotech (NASDAQ:NKGN) stock increased by 62.4% to $1.4 during Tuesday's after-market session. The company's market cap stands at $30.6 million.
    • vTv Therapeutics (NASDAQ:VTVT) stock moved upwards by 13.17% to $15.55. The company's market cap stands at $32.4 million.
    • Cerus (NASDAQ:CERS) stock increased by 9.09% to $2.16. The company's market cap stands at $391.3 million. The company's, Q4 earnings came out today.
    • Sophia Genetics (NASDAQ:SOPH) stock increased by 7.32% to $6.01. The company's market cap stands at $391.4 million. The company's, Q4 earnings came out today.
    • YS Biopharma Co (NASDAQ:YS) stock rose 6.36% to $0.65. The market value of their outstanding shares is at $122.1 million.
    • Aldeyra Therapeutics (NASDAQ:ALDX) shares increased by 6.1% to $4.17. The company's market cap stands at $245.2 million.

    Losers

    • Heart Test Laboratories (NASDAQ:HSCS) shares decreased by 22.2% to $0.14 during Tuesday's after-market session. The market value of their outstanding shares is at $8.8 million.
    • Marinus Pharma (NASDAQ:MRNS) stock decreased by 12.56% to $8.08. The company's market cap stands at $440.9 million. As per the press release, Q4 earnings came out today.
    • Compass Therapeutics (NASDAQ:CMPX) shares declined by 10.39% to $1.64. The company's market cap stands at $209.0 million.
    • Cara Therapeutics (NASDAQ:CARA) shares decreased by 8.8% to $0.83. The market value of their outstanding shares is at $45.2 million. The company's, Q4 earnings came out yesterday.
    • CareMax (NASDAQ:CMAX) stock fell 8.42% to $10.89. The company's market cap stands at $40.7 million.
    • Envoy Medical (NASDAQ:COCH) shares fell 8.01% to $8.5. The market value of their outstanding shares is at $166.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ALDX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALDX
    $CARA
    $CERS
    $CMAX

    CompanyDatePrice TargetRatingAnalyst
    Envoy Medical Inc.
    $COCH
    3/31/2026$2.50Buy
    H.C. Wainwright
    Aldeyra Therapeutics Inc.
    $ALDX
    3/18/2026$2.00Buy → Neutral
    H.C. Wainwright
    vTv Therapeutics Inc.
    $VTVT
    3/12/2026$44.00Outperform
    Evercore ISI
    Compass Therapeutics Inc.
    $CMPX
    2/13/2026$15.00Buy
    Craig Hallum
    vTv Therapeutics Inc.
    $VTVT
    1/23/2026$58.00Buy
    Roth Capital
    vTv Therapeutics Inc.
    $VTVT
    1/5/2026$67.00Buy
    TD Cowen
    Compass Therapeutics Inc.
    $CMPX
    1/5/2026Outperform
    William Blair
    Compass Therapeutics Inc.
    $CMPX
    12/3/2025$10.00Mkt Outperform
    Citizens JMP
    More analyst ratings

    $ALDX
    $CARA
    $CERS
    $CMAX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Green Kevin Dennis

    4 - CERUS CORP (0001020214) (Issuer)

    4/3/26 5:51:28 PM ET
    $CERS
    EDP Services
    Technology

    SEC Form 4 filed by Jensen Chrystal

    4 - CERUS CORP (0001020214) (Issuer)

    4/3/26 5:43:10 PM ET
    $CERS
    EDP Services
    Technology

    SEC Form 4 filed by Verma Abhimanyu

    4 - SOPHiA GENETICS SA (0001840706) (Issuer)

    4/3/26 6:59:38 AM ET
    $SOPH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALDX
    $CARA
    $CERS
    $CMAX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Patel Mona Chetan bought $125,000 worth of shares (312,500 units at $0.40), increasing direct ownership by 1,562% to 332,500 units (SEC Form 4)

    4 - Envoy Medical, Inc. (0001840877) (Issuer)

    2/17/26 4:51:51 PM ET
    $COCH
    Industrial Specialties
    Health Care

    Interim CFO Potashnick Robert bought $85,000 worth of shares (212,500 units at $0.40) (SEC Form 4)

    4 - Envoy Medical, Inc. (0001840877) (Issuer)

    2/17/26 4:49:33 PM ET
    $COCH
    Industrial Specialties
    Health Care

    Director Kantor Susan bought $38,460 worth of shares (96,150 units at $0.40), increasing direct ownership by 123% to 174,037 units (SEC Form 4)

    4 - Envoy Medical, Inc. (0001840877) (Issuer)

    2/17/26 4:47:12 PM ET
    $COCH
    Industrial Specialties
    Health Care

    $ALDX
    $CARA
    $CERS
    $CMAX
    SEC Filings

    View All

    HeartSciences Inc. filed SEC Form 8-K: Leadership Update

    8-K - HeartSciences Inc. (0001468492) (Filer)

    4/3/26 5:15:10 PM ET
    $HSCS
    Industrial Specialties
    Health Care

    SEC Form DEFA14A filed by Envoy Medical Inc.

    DEFA14A - Envoy Medical, Inc. (0001840877) (Filer)

    4/2/26 4:02:24 PM ET
    $COCH
    Industrial Specialties
    Health Care

    SEC Form DEF 14A filed by Envoy Medical Inc.

    DEF 14A - Envoy Medical, Inc. (0001840877) (Filer)

    4/2/26 4:01:38 PM ET
    $COCH
    Industrial Specialties
    Health Care

    $ALDX
    $CARA
    $CERS
    $CMAX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Envoy Medical Announces First Patients Successfully Reaching 12-Month Endpoint in Pivotal Clinical Trial for Fully Implanted Cochlear Implant

    Company Remains on Schedule for PMA Submission to FDAWhite Bear Lake, Minnesota--(Newsfile Corp. - April 1, 2026) - Envoy Medical®, Inc. (NASDAQ:COCH) ("Envoy Medical"), a hearing health company pioneering fully implanted hearing solutions, announced that the first three patients implanted in its pivotal clinical trial for the fully implanted Acclaim® cochlear implant have successfully completed their 12-month endpoint visit, marking a key milestone in the study's progress.The first three pivotal trial patients implanted at the start of 2025 are now the first to reach the 12-month follow-up evaluation point. The primary endpoints for the trial are tied to 12-month data. Achieving this critic

    4/1/26 8:00:00 AM ET
    $COCH
    Industrial Specialties
    Health Care

    HeartSciences' MyoVista Insights™ Receives Epic Toolbox Designation for ECG Management System Category

    Southlake, TX , March 25, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc.  (NASDAQ:HSCS, HSCSW)) ("HeartSciences" or the "Company"), a healthcare information technology ("HIT") company focused on advancing electrocardiography ("ECG" or "EKG") through the integration of artificial intelligence ("AI"), today announced that its MyoVista Insights™ platform has received Epic Toolbox designation for the ECG Management System category. MyoVista Insights is a cloud-native ECG management and analysis platform designed to enhance workflow efficiency and support clinical decision-making. The platform supports integration with hospital information systems and electronic health records ("EHRs"), including

    3/25/26 8:30:00 AM ET
    $HSCS
    Industrial Specialties
    Health Care

    HeartSciences to Present at Investor Summit Group Virtual Conference and Host Virtual One on One Investor Meetings

    Southlake, TX, March 24, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc.  (NASDAQ:HSCS, HSCSW)) ("HeartSciences" or the "Company"), a healthcare information technology ("HIT") company focused on advancing electrocardiography ("ECG" or "EKG") through the integration of artificial intelligence ("AI"), will present at Investor Summit Group Virtual Conference, March 25, 2026 at 12:30 pm ET. Hosted by Investor Summit Group, a premier platform connecting microcap companies with leading investors, the event provides a highly efficient forum for emerging growth companies to engage directly with institutional investors, family offices, and high-net-worth individuals. Event Details: Conference: Inves

    3/24/26 11:18:08 AM ET
    $HSCS
    Industrial Specialties
    Health Care

    $ALDX
    $CARA
    $CERS
    $CMAX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for KORSUVA issued to CARA THERAPEUTICS INC

    Submission status for CARA THERAPEUTICS INC's drug KORSUVA (ORIG-1) with active ingredient DIFELIKEFALIN has changed to 'Approval' on 08/23/2021. Application Category: NDA, Application Number: 214916, Application Classification: Type 1 - New Molecular Entity

    8/24/21 12:36:58 PM ET
    $CARA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALDX
    $CARA
    $CERS
    $CMAX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Envoy Medical with a new price target

    H.C. Wainwright initiated coverage of Envoy Medical with a rating of Buy and set a new price target of $2.50

    3/31/26 8:12:03 AM ET
    $COCH
    Industrial Specialties
    Health Care

    Aldeyra Therapeutics downgraded by H.C. Wainwright with a new price target

    H.C. Wainwright downgraded Aldeyra Therapeutics from Buy to Neutral and set a new price target of $2.00

    3/18/26 8:20:05 AM ET
    $ALDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evercore ISI initiated coverage on vTv Therapeutics with a new price target

    Evercore ISI initiated coverage of vTv Therapeutics with a rating of Outperform and set a new price target of $44.00

    3/12/26 8:55:45 AM ET
    $VTVT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALDX
    $CARA
    $CERS
    $CMAX
    Leadership Updates

    Live Leadership Updates

    View All

    Cerus Appoints Vivek Jayaraman as President and Chief Executive Officer

    William "Obi" Greenman to become Executive Chairman Leadership changes to take effect July 1, 2026 Cerus Corporation (NASDAQ:CERS) today announced that Vivek Jayaraman, Cerus' chief operating officer, will be promoted to president and chief executive officer, effective July 1, 2026. William "Obi" Greenman will become executive chairman of the board of directors. At the time of his appointment, Mr. Jayaraman will join the Board of Directors. "Following a thorough succession planning process, this transition represents a natural step as we prepare for the next phase of growth at Cerus," said Frank Witney, lead independent director on the Cerus Board of Directors. "The Board and I are de

    3/16/26 4:05:00 PM ET
    $CERS
    EDP Services
    Technology

    vTv Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

    Received $20.0 million in February 2026 from Newsoara under an amended licensing agreement Expect to complete enrollment in the CATT1 Phase 3 trial in the third quarter of 2026  Strengthened balance sheet provides funding runway well past the anticipated CATT1 Phase 3 topline readout HIGH POINT, N.C., March 10, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes ("T1D"), today reported financial results for the fourth quarter and full year ended December 31, 2025, and pro

    3/10/26 4:01:00 PM ET
    $VTVT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NKGen Biotech Names Leading Dementia Expert Bruce L. Miller, M.D. to Scientific Advisory Board

    SANTA ANA, Calif., Jan. 22, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer ("NK") cell therapeutics, today announced the appointment of Bruce L. Miller, M.D. to its Scientific Advisory Board. Dr. Miller is internationally recognized for his leadership in Alzheimer's disease ("AD"), frontotemporal dementia ("FTD"), and other neurocognitive disorders, and brings extensive scientific and clinical expertise to the Company. Dr. Miller is the A.W. and Mary Margaret Clausen Distinguished Professor in Neurology at the U

    1/22/26 8:05:00 AM ET
    $NKGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALDX
    $CARA
    $CERS
    $CMAX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Marinus Pharmaceuticals Inc.

    SC 13G/A - MARINUS PHARMACEUTICALS, INC. (0001267813) (Subject)

    11/15/24 10:35:20 AM ET
    $MRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Marinus Pharmaceuticals Inc.

    SC 13G - MARINUS PHARMACEUTICALS, INC. (0001267813) (Subject)

    11/14/24 6:39:04 PM ET
    $MRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Aldeyra Therapeutics Inc.

    SC 13G/A - Aldeyra Therapeutics, Inc. (0001341235) (Subject)

    11/14/24 4:50:29 PM ET
    $ALDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALDX
    $CARA
    $CERS
    $CMAX
    Financials

    Live finance-specific insights

    View All

    SOPHiA GENETICS Reports Fourth Quarter and Full Year 2025 Results

    BOSTON and ROLLE, Switzerland, March 3, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a global leader in AI-driven precision medicine, today reported financial results for the fourth quarter and fiscal year ended December 31, 2025. Fourth Quarter 2025 Financial ResultsRevenue was $21.7 million, up 22% year-over-yearGross margin was 67.7% on a reported basis and 73.9% on an adjusted basis, compared to 68.2% reported and 74.2% adjusted in the prior year periodIFRS net loss was $19.2 million, an increase of 27% year-over-year; Adjusted EBITDA loss was $9.9 million, an increas

    3/3/26 6:45:00 AM ET
    $SOPH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cerus Corporation Announces Full-Year and Fourth Quarter 2025 Financial Results

    2025 Total Revenue of $233.8 million, up 16% from 2024; 2025 Product Revenue of $206.1 million, up 14% from 2024 Strengthened Financial Foundation Through Strong Commercial Execution and Disciplined Operational Management Cerus Corporation (NASDAQ:CERS) announced today financial results for its full year and fourth quarter ended December 31, 2025. "Our strong 2025 results reflect our disciplined execution, as we continued to deliver on our mission of safeguarding the world's blood supply. This past year, we achieved our highest annual kit shipments, enabling an estimated 600,000 patients worldwide to receive INTERCEPT-treated blood components," said William "Obi" Greenman, Cerus' pres

    3/2/26 4:01:00 PM ET
    $CERS
    EDP Services
    Technology

    Cerus Corporation to Release Fourth Quarter and Full-Year 2025 Financial Results on March 2, 2026

    Cerus Corporation (NASDAQ:CERS) announced today its fourth quarter and full-year 2025 financial results will be released on Monday, March 2, 2026, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com. Participants may register for the call here. While not required, interested participants are encouraged to join 10 minutes prior to the start of the event. A replay will

    2/17/26 4:01:00 PM ET
    $CERS
    EDP Services
    Technology